Viking Therapeutics Shares Jump on Obesity Drug Data
Viking Therapeutics reported that patients on a less frequent dosing schedule of its experimental obesity drug maintained significant weight loss. Shares of the company surged following the positive trial results.
Xurve View
Insights:
Xurve View
VIKING THERAPEUTICS INC shares surged 35.7% to $40.85 on Tuesday afternoon after its experimental obesity treatment demonstrated durable weight-loss maintenance in a clinical study. The move marked the company's largest one-day percentage gain in over two years. The trial results bolster Viking's strategy to reduce treatment frequency and carve out share in the fast-growing weight-loss sector.
